Органосохраняющее лечение инвазивного рака мочевого пузыря

1. Карякин О.Б. Комбинированное лечение местно-распространенного и распространенного рака мочевого пузыря. Дисс. доктора мед. наук. Обнинск. — 1996.

2. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. — М. — 2001.

3. Chen W.C. et al. Concurrent Cisplatin, 5-Fluorouracil, Leucovorin, and radiotherapy for invasive bladder cancer. // Int. J. Radiat. Oncol. Biol. Phys. — 2003. — V.56 — N.3 — P.726—33.

4. Colvett K.T. et al. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. // J. Surg. Oncol. — 1996. — V.63 — N.3 — P.201—8.

5. Dunst J. et al. Organ sparing treatment of advanced bladder cancer: a 10 year experience. // Int. J. Radiat. Oncol. Biol. Phys. — 1994. — V.30. — P.261—66.

6. Henningsohn L. et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. // Radiotherapy and Oncology. — 2002. — N.62. — P.215—25.

7. McCaffrey J.A. et al. Combined-modality therapy for bladder cancer. // Oncology — 1997 — V.11(Suppl. 9). — P.18—26.

8. Roedel C. et al. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. // Int. J. Rad. Oncol. Biol. Phis. — 2002. — V.52. — N.5. — P.1303—1309.

9. Sauer R. et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organsparing treatment of bladder cancer. // Int. J. Rad. Oncol. Biol. Phis. — 1998. — V.40. — N.1. — P.121—127.

10. Shipley W.U. et al. The selection of patients for treatment by full-dose irradiation. // Cancer. — 1985. — V.55. — N.9. — P.2278—84.

11. Shipley W.U. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. // Urol. — 2002. — V.60. — P.62—68.